Brain+ (BRAINP) Investor Update summary

Commercial pipeline progress and market strategy

• Significant traction achieved in the U.K. market within 16 weeks, focusing on both NHS and private sector opportunities.

• Marketing efforts include expert-led webinars and participation in key dementia strategy events to build brand awareness and credibility.

• Outbound lead generation has yielded high conversion rates, especially in care homes and retirement villages.

• NHS engagement is targeted and strategic, focusing on high-potential trusts and leveraging recent positive budget commitments.

• Private sector deals are progressing, with annual contract values ranging from GBP 7,500 to GBP 200,000.

Sales pipeline and deal outlook

• Multiple deals in the pipeline, including a GBP 50,000 annual contract with a leading retirement community and larger proposals up to GBP 200,000.

• Care homes and retirement villages are prime targets due to their structure and resident demographics, supporting CST delivery.

• NHS deals are smaller initially but expected to grow as relationships deepen, especially at the Integrated Care Board level.

• Proposals are tailored to each establishment, with flexible pricing models and potential for pass-through costs to residents.

• International expansion is being explored, with early conversations in New Zealand and parallels drawn to successful models in the U.S.

Funding and financial outlook

• New funding will be required in the new year, primarily to support operations and commercial scaling, not R&D.

• Large sales or grants could offset some funding needs, but short-term funding is still necessary.

• Funding is focused on sales and commercial activities, with R&D supported by separate grant applications.

• Sales closures are targeted for year-end, leveraging unallocated budgets in the NHS and a strong pipeline for early 2025.